Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.
National Hospital for Neurology and Neurosurgery, Queen Square, London
National Hospital for Neurology and Neurosurgery, Queen Square, London
Dr Michael Lunn is a Consultant Neurologist, Clinical Lead in Neuroimmunology and Honorary Senior Lecturer at the National Hospital for Neurology and Neurosurgery.